METHOD FOR PREVENTION AND TREATMENT OF RENAL GRAFT REJECTION Russian patent published in 2014 - IPC A61N5/06 A61M1/36 A61K31/353 A61K38/19 A61P37/06 A61B17/03 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely transplantology, and can be used for prevention and treatment of a renal graft rejection. That is ensured by an extracorporeal photophoresis by administering a photosentiser, recovery of a mononuclear cell concentrate, dilution in normal saline and suspension exposure to ultraviolet light Additionally, the ultraviolet exposure is followed by normal saline substitution by blood plasma in the same amount. Then, the prepared mixture is added with cytokine, granulocyte-macrophage colony-stimulating factor in a dose of 80-120 ng/ml. Thereafter, the prepared composition is incubated for 90-120 minutes. Then, plasma with cytokine is substituted by normal saline in the same amount, and the prepared suspension is then injected back into blood channels. A first photophoresis session is performed on the 3rd-4th day following the renal transplantation. The first two weeks provide performing two sessions a week. For the next six weeks, one session a week is performed. For the following third month, two sessions are performed. That is followed by one session a month for the fourth, fifth and sixth months. The therapeutic course makes 15 sessions.

EFFECT: method enables reducing a rate of acute renal graft rejections considerably ensured by improving a graft function, increasing its survival and life ensured by achieving an evident immunological specific tolerance to graft alloantigens, namely as a result of providing the higher tolerogenic properties of the prepared dendritic cells by the performed translation cell therapy.

2 ex